OncLive Global

Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma

June 11th 2021

The Japan Ministry of Health, Labour, and Welfare has granted conditional and time-limited approval to teserpaturev for the treatment of patients with malignant glioma; this is the first oncolytic virus to receive approval for use in this indication or any primary brain cancer.

Duvelisib Approved in Europe for Relapsed/Refractory CLL or Follicular Lymphoma

June 9th 2021

The European Medicines Agency has granted marketing authorization to duvelisib for single-agent use in patients with relapsed/refractory chronic lymphocytic leukemia who have previously received at least 2 therapies or those with follicular lymphoma whose disease is refractory to at least 2 previous systemic therapies.

Nivolumab/Ipilimumab Approved in Europe for Frontline Unresectable Malignant Pleural Mesothelioma

June 2nd 2021

The European Commission has approved the dual immunotherapy combination of nivolumab and ipilimumab for use in the frontline treatment of adults with unresectable malignant pleural mesothelioma.

Venetoclax-Based Combos Approved in Europe for Intensive Chemo–Ineligible Newly Diagnosed AML

May 25th 2021

The European Commission has approved venetoclax for use in combination with azacitidine and decitabine in the treatment of adult patients with newly diagnosed acute myeloid leukemia who are not candidates to receive intensive chemotherapy.

Dr. Marazzi on the Goals of Examining Topotecan in COVID-19 and Cancer

May 25th 2021

Ivan Marazzi, PhD, discusses the goals for examining topotecan as a treatment for patients with COVID-19 and cancer in India and Brazil.

Cemiplimab Granted Positive EU Opinion for Advanced NSCLC and Basal Cell Carcinoma

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab for use in 2 advanced cancers: non–small cell lung cancer and basal cell carcinoma.

Frontline Pembrolizumab/Chemo Recommended for EU Approval for Select Esophageal or HER2-Negative GEJ Adenocarcinoma

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab plus platinum- and fluoropyrimidine-based chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic esophageal carcinoma or HER2-negative gastroesophageal junction adenocarcinoma with PD-L1 positivity.

Nivolumab/Ipilimumab Approaches EU Approval for Post-Chemo dMMR or MSI-H Metastatic CRC

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the combination of nivolumab and ipilimumab as an option for patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer following fluoropyrimidine-based combination therapy.

Frontline Tislelizumab Plus Chemo Improves PFS in Recurrent or Metastatic Nasopharyngeal Cancer

May 21st 2021

The combination of the anti–PD-1 tislelizumab and chemotherapy was found to significantly improve progression-free survival compared with chemotherapy alone in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer, meeting the primary end point of the phase 3 RATIONALE 309 trial.

Research Prevails in NSCLC Despite the Challenges Wrought by COVID-19

May 20th 2021

Ullas Batra, MBBS, MD, DM, discusses the durability of targeted therapy in advanced NSCLC and the movement of targeted therapy and immunotherapy into earlier stages of disease.